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ABSTRACT
Background: Intra-abdominal infections (IAIs) have different aspects to consider. One important aspect 
is the microbiological analyses, especially in the era of broad spread of resistant microorganisms. The study 
was designed to describe the clinical characteristics and microbiological profiles of community acquired IAIs.
Method: An observational study was performed on medical records of 12 months period (January to 
December 2013) in a General Hospital, Karawaci, Tangerang. Adult patients undergoing surgery for IAIs 
with positive microbiological culture and identification of microorganisms were included. Data collected were 
clinical characteristics and microbiological profiles and wereanalyzed statisticallyusing the SPSS version 17.
Results: In 12 months period of study, 17 patients of IAIs with a total of 17 intra peritoneal specimens 
were collected. A total of six microorganisms were cultured. All the IAIs were monomicrobial, with aerobic 
microorganism dominantly Gram-negative bacilli. The dominant microorganism was Escherichia coli (E. 
coli), found in 58.8% of IAIs. The most common site was appendix (41.2%), and none from small intestine. The 
susceptibility test found that piperacillin tazobactam, tigecycline, meropenem and amikacin were the most active 
antimicrobial against E. coli. Multi-drug resistant (MDR) E. coli in this study was 40%. The MDR E. coli had 
66.6% resistance to levofloxacin and ciprofloxacin, 66.6% susceptibility to ceftriaxone and ceftazidime, and 
100.0% susceptibility to amikacin.
Conclusion: The most common site of community-acquired IAIs was appendix (41.2%). E. coli is still a 
dominant microorganism with the MDR E. coli proportion of 40%. 
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ABSTRAK
Latar belakang: Infeksi intra abdomen (IIA) memiliki berbagai aspek. Salah satunya adalah analisis 
mikrobiologi, khususnya di era resistensi mikroorganisme. Penelitian ini dirancang untuk menggambarkan 
karakteristik klinis dan profil mikrobiologi IIA komunitas.
Metode: Penelitian observasional dilakukan dari data rekam medis pasien selama periode 12 bulan (Januari 
sampai Desember 2013) di  rumah sakit umum, Karawaci, Tangerang. Pasien dewasa yang menjalani pembedahan 
karena IIA dengan kultur mikrobiologik yang positif dan mikroorganisme yang teridentifikasi diikutsertakan. 
Data yang dikumpulkan adalah karakteristik klinis dan profil mikrobiologik. Data dianalisis secara statistik 
menggunakan SPSS versi 17.
Hasil: Selama periode 12 bulan didapatkan 17 pasien IIA dengan total 17 spesimen intra peritoneal. 
Didapatkan enam mikroorganisme. Semua IIA monomikrobial, dengan mikroorganisme aerobik terutama basil 
Gram-negatif. Mikroorganisme yang dominan adalah Escherichia coli (E. coli) pada 58.8% IIA. Lokasi yang 
umum adalah apendiks (41.2%), dan tidak ada dari usus halus. Tes sensitivitas mendapatkan bahwa piperacillin 
tazobactam, tigecycline, meropenem dan amikacin adalah antimikrobial paling aktif terhadap E. coli. Multi-drug 
resistant (MDR) E. coli pada studi ini 40%. MDR E. coli 66.6% resisten terhadap levofloxacin dan ciprofloxacin, 
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66.6% sensitif terhadap ceftriaxone dan ceftazidime, dan 100.0% sensitif terhadap amikacin.
Simpulan: Lokasi tersering IIA komunitas adalah apendiks (41,2%). E. coli masih merupakan mikroorganisme 
yang dominan, dengan proporsi MDR E. coli 40%. Profil mikrobiologik IIA pada penelitian ini serupa dengan 
penelitian-penelitian lainnya.
Kata kunci: infeksi intra abdomen, karakteristik klinis, profil mikrobiologi
INTRODUCTION
Intra-abdominal infections (IAIs) are complex 
disease entity with different aspects to consider. 
Several reports have emphasized the role of appropriate 
empirical antibiotic therapy to improve clinical 
success rates, reduce length of stay and decrease 
overall cost of hospitalization in IAIs.1-4 The results 
of the microbiological analyses are important for the 
therapeutic strategy, especially in the initial empirical 
antimicrobial therapy.
Many studies have found the variation of 
resistance according to the isolated microorganisms 
and the antibiotic used to provide guidance in 
choosing empirical antimicrobial therapy for selected 
infections.5-7 In the era of the broad spread of 
resistant microorganisms such as nosocomial and 
community extended-spectrum β-lactamase (ESBL) 
Enterobacteriaceae, multi drug resistance (MDR) 
Escherichia coli (E. coli), community-acquired 
methicillin-resistant Staphylococcus aureus (MRSA), 
β lactam- and vancomycinresistant enterococci (VRE), 
epidemiological studies are of great importancein 
choosing the appropriate empirical antibiotic and 
adjusting the initially inappropriate or de-escalation 
of antibiotics. This observational study was done to 
describe the clinical characteristics, and microbiological 
profiles of community-acquired IAIs.
METHOD
An observational study was performed on medical 
records of 12 months period (January to December 
2013) in a General Hospital, Karawaci, Tangerang. 
Adult patients undergoing surgery for IAIs with positive 
microbiological culture (intra-abdominal sample) 
and identification of microorganisms were included. 
Data collected were clinical characteristics of patients 
(age, sex, comorbidities, type of infection, type of 
peritonitis, localization of lesions), and microbiological 
profiles (microorganisms identification and antibiotic 
susceptibilities of bacterial isolates). Nosocomial 
infections were excluded. Nosocomial IAIs was defined 
as an infection absent upon admission that became 
evident 48 hours or more after admission inpatients 
hospitalized for a reason other than IAIs.8 Patients with 
post-operative infections were considered as nosocomial 
cases. Comorbidities included chronic kidney disease, 
chronic heart failure, diabetes mellitus, hypertension, 
malnutrition and malignancy. Microbiological analyses 
and susceptibility testing were performed using the VITEK 
2 Compact and according to the recommendations of the 
Clinical Laboratory and Standards Institute (CLSI).8,9 
Multidrug resistance (MDR) was defined as resistance to 
three or more groups of antimicrobials. After entry into a 
computerized database, the data was analyzed statistically 
using the software package SPSS version 17. Results 
are expressed as median (range), mean and standard 
deviation for continuous variables, and the number with 
the corresponding percentage for qualitative variables. 
The epidemiology of the microorganisms isolated inintra-
abdominal samples and their susceptibility to antibiotics 
is described and analyzed.
RESULTS
In 12 months period of study on January to December 
2013 17 patients of IAIs were included. Male to female 
ratio was 1.3 : 1. Median age was 44 year old with 
range 4–78 year old. Among these patients, a total of 17 
intra peritoneal specimens were collected. The clinical 
characteristics of patients are described in Table 1.
Table 1.Clinical characteristics of patients
Clinical characteristics Frequencyn (%)
Co-morbidities
Chronic kidney disease
Chronic heart failure
Diabetes mellitus
Hypertension 
Malnutrition 
Malignancy
0 (0.0%)
0 (0.0%)
2 (11.8%)
0 (0.0%)
1 (5.9%)
1 (5.9%)
Type of peritonitis
Generalized 
Localized 
7 (41.2%)
10 (58.5%)
Localization of lesions
Appendix 
Colon 
Small intestine 
Biliary tract 
Urinary tract
Reproduction system
7 (41.2%)
3 (17.6%)
0 (0.0%)
1 (5.9%)
4 (23.5%)
2 (11.8%)
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A total of 6 microorganisms were cultured. 
All the IAIs were monomicrobial, with aerobic 
microorganism dominantly Gram-negative bacilli. No 
anaerobic microorganism was found.The dominant 
microorganism was E. coli, found in 58.8% of IAIs. 
According to the localization of infections, the 
most common site was appendix (41.2%), and none 
from small intestine. Microorganisms isolated from 
patients with IAIs are described in Table 2 and their 
localizations are described in Table 3. Antimicrobials 
susceptibilities (% susceptible) of bacteria isolated 
from patients with IAIs are described in Table 4. 
The susceptibility test found that piperacillin 
tazobactam, tigecycline, meropenem and amikacin 
were the most active antimicrobial against E. coli. MDR 
E. coli in this study were 40%, the MDR E. coli found 
to be resistant to the commonly used antimicrobials 
of amoxicillin, trimethoprim-sulfamethoxazole, and 
ciprofloxacin.
Table 2. Microorganisms isolated from patients withintra-
abdominal infections
Microorganisms Frequencyn (%)
Aerobes 
Gram-negative bacilli 
Escherichia coli 
Morganella morganii ssp 
Acinetobacter baumannii 
Pseudomonas aeruginosa
Gram-positive cocci 
Streptococcus spp. 
Staphylococcus aureus 
10 (58.8%)
1 (5.9%)
2 (11.9%)
1 (5.9%)
1 (5.9%)
2 (11.8)
Table 3. Microorganisms isolated from patients with intra-abdominal infections according to localization of infections
Localization 
Escherichia
coli
(n = 10)
Morganella 
morganii ssp.
(n = 1)
Acinetobacter 
baumannii
(n = 2)
Pseudomonas 
aeruginosa
(n = 1)
Streptococcus spp.
(n = 1)
Staphylococcus aureus
(n = 2)
Appendix
Biliary tract 
Colon 
Reproduction system
Urinary tract
7
0
1
2
0
0
0
1
0
0
0
0
1
0
1
0
0
0
0
1
0
1
0
0
0
0
0
0
0
2
Table 4. Antimicrobials susceptibilities of bacteria isolated from patients with IAIs
Antimicrobial agent
Susceptible (%)
Escherichia
coli
(n = 10)
Morganella 
morganii ssp.
(n = 1)
Acinetobacter 
baumannii
(n = 2)
Pseudomonas 
aeruginosa
(n = 1)
Streptococcus 
spp.
(n = 1)
Staphylococcus 
aureus
(n = 2)
Amoxicillin 10.0 0.0 NA NA NA 0.0
Ampicillin sulbactam 50.0 0.0 50.0 0.0 100.0 100.0
Piperacillin tazobactam 100.0 100.0 50.0 100.0 100.0 100.0
Cefotaxime 80.0 100.0 50.0 NA NA 100.0
Ceftriaxone 80.0 100.0 0.0 0.0 NA 100.0
Ceftazidime 80.0 100.0 50.0 100.0 0.0 100.0
Cefepime 80.0 50.0 0.0 100.0 NA 100.0
Gentamicin 60.0 100.0 50.0 100.0 100.0 100.0
Amikacin 100.0 100.0 100.0 100.0 0.0 NA
Ciprofloxacin 60.0 100.0 50.0 100.0 100.0 100.0
Levofloxacin 60.0 100.0 0.0 100.0 NA 100.0
Co–trimoxazole 20.0 100.0 100.0 0.0 NA 100.0
Imipenem 100.0 NA 50.0 100.0 100.0 100.0
Meropenem 90.0 100.0 100.0 100.0 100.0 100.0
Aztreonam 70.0 100.0 0.0 0.0 NA NA
Tigecycline 100.0 0.0 100.0 0.0 NA 100.0
       Table 5. Antimicrobials susceptibilities of Eschericia coli isolated from patients with IAIs
Sex Age
A
m
oxicillin
A
m
picillin
 subactam
Piperacilin
 Tazobactam
C
efotaxim
e
C
eftriaxone
C
eftazidim
e
C
efepim
e
G
entam
icin
A
m
ikacin
C
iprofloxacin
Levofloxacin
C
o – 
 trim
oxazole
Im
ipenem
M
eropenem
A
ztreonam
Tigecycline
M 44 R S S S S S S R S R R R S S S S
F 19 R R S R R R R R S R R R S S R S
F 52 R S S R R R R S S R R R S S R S
M 4 R R S S S S S S S R R R S S S S
F 6 R R S S S S S R S S S R S S S S
M 54 R R S S S S S R S S S R S S S S
M 13 S S S S S S S S S S S S S R R S
F 28 R S S S S S S S S S S R S S S S
M 45 R S S S S S S S S S S S S S S S
M 13 R R S S S S S S S S S R S S S S
       M: male; F: female; R: resistant; S: sensitive
In this study, MDR E. coli had 66.6% resistance 
to levofloxacin and ciprofloxacin, 100.0% resistance 
to amoxicillin, 66.6% susceptibility to ceftriaxone 
and ceftazidime, 66.6% resistance to gentamicin and 
100.0% susceptibility to amikacin. Antimicrobials 
susceptibilities of E. coli isolated from patients with 
IAIs are described in Table 5. Patients with MDR E. 
coli are no. 1–6.
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trimethoprim-sulfamethoxazole, and ciprofloxacin. 
These resistance profiles were common and could be 
associated with a number of known acquired resistance 
genes.3 In this study, MDR E. coli has 66.6% resistance 
to levofloxacin and ciprofloxacin. In a study in Sudan, 
MDR E. coli showed high resistance to ofloxacin and 
ciprofloxacin (55.9 % and 57.4% respectively).13 The 
hypothesized causes were the inappropriate use of 
fluoroquinolones for humans and prolonged use of 
low dose of the more potent fluoroquinolones such 
as ciprofloxacin.18,19 The study in Sudan showed high 
resistance to 2nd and 3rd generation cephalosporins, 
whereas this study showed 66.6% susceptibility to 
ceftriaxone and ceftazidime. The hypothesized cause 
wasthe presence of ESBL in these strains.13,20 In 
according to other studies13,14,21 MDR E. coli in this 
study showed 100.0% susceptibility to amikacin. The 
hypothesized cause is that amikacin is a very powerful 
antimicrobial used only in hospital settings and not 
as first-line antimicrobial.13 Other microorganisms 
in this study were not evaluated due to few numbers. 
The weakness of this study is, that as an observational 
study on medical records there were no standards to 
some data. The significance of susceptibility test from 
studies involving fewer than 30 organisms is difficult 
to interpret.22
CONCLUSION
This study concluded that the most common site of 
community-acquired IAIs was appendix and E. coli is 
still a dominant microorganism in community-acquired 
IAIs. Microbiological profiles of IAIs in this study were 
similar to other studies.
REFERENCES
1. Roehrborn A, Thomas L, Potreck O, Ebener C, Ohmann 
C, Goretzki PE, et al. The microbiology of postoperative 
peritonitis. Clin Infect Dis 2001;33:1513–9.
2. Sotto A, Lefrant JY, Fabbro-Peray P, Muller L, Tafuri 
J, Navarro F, et al. Evaluation of antimicrobial therapy 
management of 120 consecutive patients with secondary 
peritonitis. J Antimicrob Chemother 2002;50:569–76.
3. Seguin P, Laviolle B, Chanavaz C, Donnio P-Y, Gautier-
Lerestif AL, Campion JP, et al. Factors associated with 
multidrug-resistant bacteria in secondary peritonitis: impact 
on antibiotic therapy. Clin Microbiol Infect 2006;12:980–5.
4. Montravers P, Lepape A, Dubreuil L, Gauzit R, Pean Y, 
Benchimol D, et.al. Clinical and microbiological profiles 
of community-acquired and nosocomial intra-abdominal 
infections: results of the French prospective, observational 
EBIIA study. J Antimicrob Chemother 2009;63:785–94.
DISCUSSION
Several epidemiological studies on microbiological 
profiles of IAIs at single centre or international level 
have been published recently.1,2,5-7 The microbiological 
profile of IAIs is the summary of transient or 
persistent normal gastrointestinal flora with potentially 
pathogenic microorganisms, including the Gram-
positive, Gram-negative, anaerobic bacteria and fungal. 
The microbiological profile is of great importance 
inchoosing the appropriate empirical antibiotic and 
adjusting the initially inappropriateor de-escalation 
of antibiotics. 
About 20–25% of cultures in secondary peritonitis 
were negative, 25% were monomicrobial and 50% were 
polymicrobial.5,6 To conclude, IAIs are polymicrobial 
with an aerobic and anaerobic component, with 
the aerobic component inducing local or systemic 
inflammation, and the anaerobic component inducing 
abscess formation.7 In this study, no culture was 
negative and all IAIs were monomicrobial. The possible 
explanation is most of the IAIs were community-
acquired from appendicitis. 
In studies of community-acquired IAIs, E. coli were 
found in more than 50% isolates.1,3 E. coli, Streptococcus 
spp. and Bacteroides fragilis (B. fragilis) were the most 
frequently isolated microorganisms.4-6 This study also 
found E. coli as the most frequent microorganism in 
IAIs (58.8%), followed by Acinetobacter baumannii and 
Staphylococcusaureus (11.8% and 11.8% respectively).
Location of the lesions of secondary peritonitis 
influences the spectrum of pathogens involved, as gastro-
duodenal, small intestine, appendix and colorectal have 
a different flora in terms of microorganism species and 
density.10 Gram-negative and anaerobic bacteria are 
dominant in IAIs from colorectal or appendix. Gram-
positive bacteria and yeasts are dominant in IAIs from 
gastroduodenal. There is a relative balance between 
the four groups of microorganisms in IAIs from small 
intestine.11 In this study the dominant microorganism 
was E. coli (58.8%), a Gram-negative bacteria, as the 
most common site of infection was appendix (41.2%). 
E. coli was found in all IAIs originating from appendix.
MDR E. coli in this study were 60%, whereas studies 
in Africa and South America showed prevalence of 70-
90%, and studies in Europe and USA showed lower 
prevalence.12-17 The emergence of different MDR E. 
coli phenotypes with resistance to three or more groups 
of antimicrobials has been reported in other studies and 
considered as a serious health problem.15-17 The MDR 
E. coli in this study was found to be multi-resistant 
to the commonly used antimicrobials of amoxicillin, 
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy24
Nata Pratama Hardjo Lugito, Cucunawangsih, Andree Kurniawan, Margaret Merlyn Tjiang
5. Paterson DL, Rossi F, Baquero F, Hsueh P-R, Woods GL, 
Satishchandran V, et al. In vitro susceptibilities of aerobic 
and facultative Gram-negative bacilli isolated from patients 
with intra-abdominal infections worldwide: the 2003 study 
for monitoring Antimicrobial Resistance Trends (SMART). 
J Antimicrob Chemother 2005;55:965–73.
6. Rossi F, Baquero F, Hsueh PR, Paterson DL, Bochicchio 
GV, Snyder TA, et al. In vitro susceptibilities of aerobic and 
facultatively anaerobic Gram-negative bacilli isolated from 
patients with intra-abdominal infections worldwide: 2004 
results from SMART (Study for Monitoring Antimicrobial 
Resistance Trends). J Antimicrob Chemother 2006;58:205–10.
7. Baquero F, Hsueh PR, Paterson DL, Rossi F, Bochicchio GV, 
Gallagher G, et al. In vitro susceptibilities of aerobic and 
facultatively anaerobic Gram-negative bacilli isolated from 
patients with intra-abdominal infections worldwide: 2005 
results from Study for Monitoring Antimicrobial Resistance 
Trends (SMART). Surg Infect (Larchmt) 2009;10:99-104.
8. Neeley W, Davis G, Davis RR, Marquaardt B, Nickel KL, 
Parvin CA, et al. Autoverification of Clinical Laboratory 
Test Results; Approved Guideline (AUTO10-A). Wayne, 
PA: Clinical and Laboratory Standards Institute 2006.p.5-7. 
9. Barenfanger J, Drake C, Kacich G. Clinical and financial 
benefits of rapid bacterial identification and antimicrobial 
susceptibility testing. J Clin Microbiol 1999;37:1415-8.
10. Blot S, Waele JJD, Vogelaers D. Essentials for selecting therapy 
for intra-abdominal infections. Drugs 2012;72:e17-e32. 
11. de Ruiter J, Weel J, Manusama E, Kingma WP, van der Voort 
PHJ. The epidemiology of intra-abdominal flora in critically 
ill patients with secondary and tertiary abdominal sepsis. 
Infection 2009;37:522-7.
12. Kibret M, Abera B. Antimicrobial susceptibility of E. coli 
from clinical sources in northeast Ethiopia. Afr Health Sci 
2011;11(Suppl 1):S40–S45.
13. Ibrahim ME, Bilal NE, Hamid M. Increased multi-drug 
resistant Escherichia coli from hospitals in Khartoum state, 
Sudan. Afr Health Sci 2012;12:368-75.
14. Salem MM, Muharram M, Alhosiny IM. Distribution of 
classes 1 and 2 integrons among multi drug resistant E. coli 
isolated from hospitalized patients with urinary tract infection 
in Cairo, Egypt. Aust J Basic Appl Sci 2010;4:398-407.
15. Bartoloni A, Pallecchi L, Benedetti M, Ferenandez C, 
Vallejos Y, Guzman E, et al. Multidrug-resistant commensal 
Escherichia coli in children, Peru and Bolivia. Emerg Infect 
Dis 2006;12:907-13.
16. Oteo J, Lázaro E, de Abajo FJ, Baquero F, Campos J. Spanish 
members of EARSS. Antimicrobial-resistant invasive 
Escherichia coli, Spain. Emerg Infect Dis 2005;11:546-53.
17. Sahm DF, Thornsberry C, Mayfield DC, Jones ME, Karlowsky 
JA. Multidrug-resistant urinary tract isolates of Escherichia 
coli: prevalence and patient demographics in the United States. 
Antimicrob Agents Chemother 2001;45:1402-26.
18. Drago L, Nicola L, Mattina R, Vecchi ED. In vitro lselection 
of resistance in Escherichia coli and Klebsiella spp. at in vivo 
fluoroquinolone concentrations. BMC Microbiol 2010;10:119.
19. Chenia, HY, Pillay B, Pillay D. Analysis of the mechanisms 
of fluoroquinolone resistance in urinary tract pathogens. J 
Antimicrob Chemother 2006;58:1274-8.
20. Kader AA, Kumar AK. Prevalence of extended spectrum 
β-lactamase among multidrug resistant Gram-negative 
isolates from a general hospital in Saudi Arabia. Saudi Med 
J 2004;25:570-4.
21. Sahuquillo-Arce JM, Selva M, Perpinan H, Gobernado M, 
Armero C, Lopez-Quilez A, et al. Antimicrobial resistance 
in more than 100,000 Escherichia coli isolates according to 
culture site and patient age, gender, and location. Antimicrob 
Agents Chemother 2011;55:1222-8.
22. Cornaglia G, Hryniewicz W, Jarlier V, Kahlmeter G, 
Mittermayer H, Stratchounski L,et  al .  European 
recommendations for antimicrobial resistance surveillance. 
Clin Microbiol Infect 2004;10:349–83.
Correspondence: 
Nata Pratama Hardjo Lugito 
Department of Internal Medicine 
Faculty of Medicine 
University of Pelita Harapan 
Jl. Boulevard Jendral Sudirman Tangerang 15811 Indonesia 
Phone: +62-21-54210130; Facsimile:+62-21-54210133 
E-mail: nata.lugito@uph.edu
